Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAH0968 in HER2-positive Advanced Solid Tumors
NCT04934514Phase 2Unknown
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of IAH0968 in solid tumor and biliary tract cancer (BTC) (4 arms), sponsored by SUNHO BioPharmaceutical. Primary endpoints: Adverse Events, Dose Limiting Toxicities and 1 more. Status: unknown.
02
Drugs
IAH0968
03
Conditions
solid tumorbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04934514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934514.